ABSTRACT
Intracellular DNA triggers interferon release during the innate immune response. Cyclic GMP-AMP synthase (cGAS) senses intracellular double-stranded DNA not only in response to viral infection but also under autoimmune conditions. Measuring the levels of cyclic GMP-AMP (cGAMP) as a second messenger of cGAS activation is important to elucidate the physiological and pathological roles of cGAS. Therefore, we generated monoclonal antibodies against cGAMP using hybridoma technology to test antibody specificity and establish methods to detect intracellular cGAMP. The resulting cGAMP-specific antibody enabled the development of a time-resolved fluorescence energy transfer assay with a quantifiable range of 0.1 nM to 100 nM cGAMP. Using this assay, we detected cellular and tissue cGAMP. We confirmed that the cGAMP antibody successfully targeted intracellular cGAMP through immunocytochemical analyses. These results demonstrated that the cGAMP antibody is a powerful tool that allows determining cGAS involvement in autoimmunity and disease pathology at the cell and tissue levels.
Subject(s)
Antibodies, Monoclonal/immunology , Autoimmune Diseases of the Nervous System/metabolism , Fluorescence Resonance Energy Transfer , Immunohistochemistry , Neoplasms/metabolism , Nervous System Malformations/metabolism , Nucleotides, Cyclic/metabolism , Nucleotidyltransferases/metabolism , Animals , Antibody Specificity , Autoimmune Diseases of the Nervous System/genetics , Autoimmune Diseases of the Nervous System/immunology , Autoimmunity , Biomarkers/metabolism , Caco-2 Cells , Disease Models, Animal , Enzyme Activation , Exodeoxyribonucleases/deficiency , Exodeoxyribonucleases/genetics , HEK293 Cells , HL-60 Cells , High-Throughput Screening Assays , Humans , Mice, Inbred C57BL , Mice, Knockout , Neoplasms/immunology , Nervous System Malformations/genetics , Nervous System Malformations/immunology , Nucleotides, Cyclic/immunology , Nucleotidyltransferases/genetics , Phosphoproteins/deficiency , Phosphoproteins/genetics , Predictive Value of Tests , Reproducibility of ResultsABSTRACT
CCR6 has been implicated in both autoimmune diseases and non-autoimmune diseases. Thus, inhibition of CCR6-dependent cell migration is an attractive strategy for their treatment. An orally available small molecule inhibitor of CCR6 could therefore be a useful biological probe for the pathophysiological studies. Initial SAR study of a hit compound provided potent N-benzenesulfonylpiperidine derivatives that suppressed CCL20-induced Gi signals. By subsequent scaffold morphing of the central ring and further optimization, we identified a novel series of 1,4-trans-1-benzenesulfonyl-4-aminocyclohexanes as potent and selective CCR6 inhibitors with good pharmacokinetic properties. Our compounds showed good correlation between Gi signal inhibitory activity and cell migration inhibitory activity in human CCR6-transfected CHO cells. In addition, representative compound 35 potently inhibited CCR6-dependent cell migration and the increase in ERK phosphorylation in human primary cells. Therefore, the compound could be used effectively as a biological probe against human CCR6.
Subject(s)
Amines/pharmacology , Cyclohexanes/pharmacology , Piperidines/pharmacology , Receptors, CCR6/antagonists & inhibitors , Small Molecule Libraries/pharmacology , Amines/chemical synthesis , Amines/chemistry , Animals , B-Lymphocytes/drug effects , CHO Cells , Cell Movement/drug effects , Cricetulus , Cyclohexanes/chemical synthesis , Cyclohexanes/chemistry , Dose-Response Relationship, Drug , Haplorhini , Humans , Molecular Structure , Piperidines/chemical synthesis , Piperidines/chemistry , Receptors, CCR6/metabolism , Small Molecule Libraries/chemical synthesis , Small Molecule Libraries/chemistry , Structure-Activity RelationshipABSTRACT
Novel small molecules were synthesized and evaluated as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists for the treatment of inflammatory and autoimmune diseases. A hit compound, 1, was discovered by high-throughput screening of our compound library. The structure-activity relationship (SAR) study of compound 1 showed that the introduction of a chlorine group at the 3-position of 4-cyanophenyl moiety increased the potency and a 3-methylpentane-1,5-diamide linker is favorable for the activity. The carbazole moiety of 1 was also optimized; a quinazolinedione derivative 18i suppressed the increase of IL-17A mRNA level in the lymph node of a rat model of experimental autoimmune encephalomyelitis (EAE) upon oral administration. These results indicate that the novel quinazolinedione derivatives have great potential as orally available small-molecule RORγt inverse agonists for the treatment of Th17-driven autoimmune diseases. A U-shaped bioactive conformation of this chemotype with RORγt protein was also observed.
Subject(s)
Nuclear Receptor Subfamily 1, Group F, Member 3/agonists , Quinazolinones/chemistry , Administration, Oral , Animals , Binding Sites , Drug Inverse Agonism , Encephalomyelitis, Autoimmune, Experimental/drug therapy , Encephalomyelitis, Autoimmune, Experimental/pathology , Encephalomyelitis, Autoimmune, Experimental/veterinary , Female , Humans , Inhibitory Concentration 50 , Interleukin-17/genetics , Interleukin-17/metabolism , Jurkat Cells , Molecular Docking Simulation , Nuclear Receptor Subfamily 1, Group F, Member 3/genetics , Nuclear Receptor Subfamily 1, Group F, Member 3/metabolism , Protein Binding/drug effects , Protein Structure, Tertiary , Quinazolinones/administration & dosage , Quinazolinones/metabolism , Quinazolinones/pharmacology , Rats , Rats, Inbred Lew , Solubility , Structure-Activity Relationship , Th17 Cells/cytology , Th17 Cells/drug effects , Th17 Cells/metabolismABSTRACT
A series of novel phenylglycinamides as retinoic acid receptor-related orphan receptor-gamma t (RORγt) inverse agonists were discovered through optimization of a high-throughput screen hit 1. (R)-N-(2-((3,5-Difluoro-4-(trimethylsilyl)phenyl) amino)-1-(4-methoxyphenyl)-2-oxoethyl)-3-hydroxy-N-methylisoxazole-5-carboxamide (22) was identified as one of the best of these compounds. It displayed higher subtype selectivity and specificity over other nuclear receptors and demonstrated in vivo potency to suppress the transcriptional activity of RORγt in a mouse PD (pharmacodynamic) model upon oral administration.